AE37
Phase 2- Indications
- HER2-positive breast cancer, Prostate cancer
Company intelligence / Profile preview
Antigen Express
Wellesley Hills/Worcester*, Massachusetts, United Statesbionity.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Lead candidate AE37 completed Phase II trials in HER2-expressing breast cancer. The vaccine demonstrated the ability to stimulate both CD4+ and CD8+ T cell responses. Other pipeline candidates are at preclinical or early clinical stages targeting infectious diseases and additional cancers.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Peptide vaccinesDNA vaccinesImmunotherapeutic vaccines
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Merck collaboration for triple negative breast cancer trial development.
Beyond the preview
Go deeper on Antigen Express.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Antigen Express.